What to watch with Pharmakogenetik Medicheck and menopause?

When combining pharmacogenetics (e.g., Medicheck) with menopause management, caution is warranted: genetic variants can influence the metabolism of hormone replacement therapy (HRT), antidepressants, or other drugs, but the evidence is often limited and not clinically validated for all compounds. Menopause itself alters hormonal status and can modulate drug effects – a genetic test alone does not replace medical supervision. For instance, CYP2D6 or CYP3A4 variants may affect the metabolism of estrogens or SSRIs, yet the effects are modest and confounded by lifestyle, diet, and other factors. Moreover, many pharmacogenetic markers have been studied in premenopausal populations; transferability to postmenopausal women is uncertain. A responsible approach: treat test results as clues, not diagnoses; watch for interactions with over‑the‑counter products (e.g., St. John’s wort); and always coordinate therapy with a physician. Evidence: mostly mechanistic/association studies, no large RCTs for menopause‑specific pharmacogenetics.